Urology News and Research

Latest Urology News and Research

Taiho Oncology announces acceptance of TAS-102 NDA for review by FDA

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced the New Drug Application (NDA) for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), has been accepted for review by the U.S. Food and Drug Administration.

23 Feb 2015

Actavis obtains final approval from FDA for generic Subutex

Actavis plc today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Reckitt Benckiser's Subutex (Buprenorphine 2 mg and 8 mg sublingual tablets).

21 Feb 2015

Research findings lay groundwork for improving treatment assessment for men with prostate cancer

UCLA researchers have found that radiation therapy is the most common treatment for men with prostate cancer regardless of the aggressiveness of the tumor, risk to the patient and overall patient prognosis. These findings lay the groundwork for improved treatment assessment by physicians and to better inform men fighting the disease.

20 Feb 2015

Leaf Healthcare's wireless patient monitoring system can improve pressure ulcer prevention processes

Clinicians from the Veterans Affairs Medical Center in Boise, Idaho, will demonstrate that Leaf Healthcare's new, wireless patient monitoring system can significantly improve a caregiver's pressure ulcer prevention processes. Their presentation will take place at the National Pressure Ulcer Advisory Panel Biennial Conference in Orlando, Fla., this week.

19 Feb 2015

Findings may help doctors recommend appropriate treatments, improve patient outcomes

Like a car's front and back bumpers, your cell's chromosomes are capped by "telomeres" that protect this genetic material against deterioration. Still, after enough replications, a chromosome's telomeres break down and once they reach a certain point of degradation, the cell dies. This is one reason that cells are mortal: telomeres only last so long. That is, unless the enzyme telomerase builds new material onto the worn telomeres to reinforce these chromosomal "bumpers". Telomere repair can be a good thing, but in some cases it's not: overactive telomerase can lengthen telomeres until a cell becomes immortal…leading to cancer.

18 Feb 2015

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

Cabazitaxel therapy may be more effective in treating prostate cancer

Prostate cancer is the second leading cause of cancer for men in the United States. Only one class of chemotherapy called taxanes is effective against the disease.

17 Feb 2015

Actavis releases generic version of Pulmicort RESPULES

Actavis plc today announced that it has launched its generic version of AstraZeneca's Pulmicort RESPULES® (budesonide inhalation suspension) 0.25 and 0.5 mg vials following a ruling from the United States District Court for the District of New Jersey that (i) United States Patent No. 7,524,834 is invalid, and (ii) AstraZeneca's request for a permanent injunction is denied.

13 Feb 2015

Sanford Health wins LocumTenens.com's Best Places to Practice Locum Tenens contest

Sanford Health, the nation's largest rural, not-for-profit healthcare system, has been named the winner of LocumTenens.com's Best Places to Practice Locum Tenens contest.

12 Feb 2015

GenomeDx announces publication of positive validation study for Decipher Prostate Cancer Classifier

GenomeDx Biosciences today announced the publication of a positive validation study for the Decipher® Prostate Cancer Classifier, a genomic test for prostate cancer. The study, published in the Journal of Clinical Oncology, showed that patients with low genomic risk (as determined by Decipher) may be optimally managed with observation after radical prostatectomy (prostate surgery), while those with high genomic risk (as determined by Decipher) may be better managed earlier with adjuvant radiotherapy.

10 Feb 2015

Virginia Hospital Center joins Mayo Clinic Care Network

Mayo Clinic and Virginia Hospital Center today announced Virginia Hospital Center as a member of the Mayo Clinic Care Network, a national network of organizations committed to better serving patients and their families through collaboration. Members of the network have access to Mayo Clinic knowledge and expertise to give their patients additional peace of mind when making health care decisions while continuing to offer the highest quality and value of care close to home.

9 Feb 2015

Three Keck Medicine scientists of USC receive $4.3 million from CIRM for stem cell research

Three scientists from Keck Medicine of the University of Southern California have won grants exceeding $4.3 million from the California Institute for Regenerative Medicine for research that includes creating a temporary liver for transplant patients, finding novel ways to treat immune disorders and blood diseases and developing a new animal model for exploring diseases like heart failure, diabetes and neurodegenerative diseases.

5 Feb 2015

Researchers develop optimised PSA screening programme for prostate cancer

As an indicator of prostate cancer, the PSA test is regarded in urology as highly controversial since it is not always unequivocal. A team of researchers from the Comprehensive Cancer Center at the MedUni Vienna and Vienna General Hospital has now developed a programme that compensates the shortfalls of PSA screening with methods from personalised medicine. As a result, prostate cancer screening is able to reach a new level of quality.

4 Feb 2015

New book debunks myth that failed potty training is parent or child’s fault

Patience is a virtue, unless your child suffers from one of the most common, and frustrating, childhood conditions: bedwetting.

2 Feb 2015

Immunomic Therapeutics, Astellas Pharma sign license deal to develop LAMP-vax DNA vaccines

Immunomic Therapeutics, Inc. ("Immunomic Therapeutics"), a company developing next-generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive license agreement for Japan to develop and commercialize JRC2-LAMP-vax, Immunomic Therapeutics' vaccine designed to treat allergies induced by Japanese red cedar pollen.

30 Jan 2015

Study finds no evidence that testosterone replacement therapy increases cardiovascular risk

Fears of a link between testosterone replacement therapy and cardiovascular risk are misplaced, according to a review published in this month's Mayo Clinic Proceedings. The therapy has come under widespread scrutiny in recent months, including by a federal Food and Drug Administration panel convened last fall.

28 Jan 2015

Close, active monitoring of small renal tumors linked to low rates of death

In patients likely to have surgery, close, active monitoring of small renal tumors confined to the kidneys is associated with low rates of tumor growth or death, according to a study by a researcher at the Icahn School of Medicine at Mount Sinai published in the September issue of The Journal of Urology.

22 Jan 2015

ENIGMA scientists discover eight genetic mutations that may erode or boost brain tissue

In the largest collaborative study of the brain to date, researchers from the Keck School of Medicine of the University of Southern California led a global consortium of 190 institutions to identify eight common genetic mutations that appear to age the brain an average of three years. The discovery could lead to targeted therapies and interventions for Alzheimer's disease, autism and other neurological conditions.

22 Jan 2015

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter Plc. and Actavis plc today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia.

20 Jan 2015

New study characterizes genetic underpinnings of phyllodes tumors

A new study from researchers at the University of Michigan Comprehensive Cancer Center characterizes the genetic underpinnings of a rare type of breast tumor called phyllodes tumors, offering the first comprehensive analysis of the molecular alterations at work in these tumors.

16 Jan 2015

Urology News and Research

Latest Urology News and Research

Taiho Oncology announces acceptance of TAS-102 NDA for review by FDA

Actavis obtains final approval from FDA for generic Subutex

Research findings lay groundwork for improving treatment assessment for men with prostate cancer

Leaf Healthcare's wireless patient monitoring system can improve pressure ulcer prevention processes

Findings may help doctors recommend appropriate treatments, improve patient outcomes

Actavis provides overview of standalone global pharmaceutical development pipeline

Cabazitaxel therapy may be more effective in treating prostate cancer

Actavis releases generic version of Pulmicort RESPULES

Sanford Health wins LocumTenens.com's Best Places to Practice Locum Tenens contest

GenomeDx announces publication of positive validation study for Decipher Prostate Cancer Classifier

Virginia Hospital Center joins Mayo Clinic Care Network

Three Keck Medicine scientists of USC receive $4.3 million from CIRM for stem cell research

Researchers develop optimised PSA screening programme for prostate cancer

New book debunks myth that failed potty training is parent or child’s fault

Immunomic Therapeutics, Astellas Pharma sign license deal to develop LAMP-vax DNA vaccines

Study finds no evidence that testosterone replacement therapy increases cardiovascular risk

Close, active monitoring of small renal tumors linked to low rates of death

ENIGMA scientists discover eight genetic mutations that may erode or boost brain tissue

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

New study characterizes genetic underpinnings of phyllodes tumors

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Urology News and Research

Latest Urology News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in